Collagen News and Research

Latest Collagen News and Research

Kensey Nash announces financial results for second quarter of fiscal year 2010

Kensey Nash Corporation, a leading medical technology company that provides innovative solutions and technologies for a wide range of medical procedures, today reported the results for its three and six months ended December 31, 2009.

28 Jan 2010

Suneva Medical to present interim data from its Artefill study for NLF correction at the Maui Derm 2010

Suneva Medical, a privately-held aesthetic medical device company, today announced 18-month interim results from its prospective, open-label, five-year safety and patient satisfaction study on Artefill for nasolabial fold (NLF) correction. The study assessed adverse events with Artefill starting at 6-months post treatment. Initial results show the incidence of adverse events with Artefill compare favorably to the current label, and that the majority of patients (88%) reported a high satisfaction rating. Upon completion, this will be the largest and longest duration prospective U.S. clinical study of any dermal filler.

27 Jan 2010

Scientific/technical review for XIAFLEX' European MAA commences

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that its partner Auxilium Pharmaceuticals, Inc. announced that Pfizer Inc. received notification from the European Medicines Agency that the Marketing and Authorization Application (MAA) for XIAFLEX™ for the treatment of Dupuytren's disease (a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers) has completed the validation phase successfully and that the scientific/technical review procedure commenced today.

21 Jan 2010

Pfizer and Auxilium Pharmaceuticals announce completion of European MAA validation phase for XIAFLEX

Pfizer Inc. and Auxilium Pharmaceuticals, Inc. today announced that Pfizer received notification from the European Medicines Agency that the Marketing Authorization Application (MAA) for XIAFLEX™ (collagenase clostridium histolyticum), a novel, first-in-class, biologic for the treatment of Dupuytren’s contracture (a condition resulting in the contracture of the fingers into the palm), has completed the validation phase successfully. As a result, the scientific/technical review procedure commenced on 21 January 2010.

21 Jan 2010

Wound Care Innovations' CellerateRx highlighted at the SuperBones East conference

Wound Management Technologies, Inc., a rapidly growing provider of specialty medical products, announced today that its subsidiary Wound Care Innovations was highlighted as part of a presentation exhibited at the SuperBones East conference in Nassau, Bahamas, on January 14-17. The SuperBones Conference has a great reputation for high quality educational lectures and workshops and places top national speakers at the podium.

20 Jan 2010

Study data on Artefill for treating atrophic acne scars presented at the Orlando Dermatology Conference

Suneva Medical, a privately-held aesthetic medical device company, provided a research grant to support an investigator-sponsored research study to evaluate the degree of correction and patient satisfaction after injection of atrophic scars with Artefill. The data was presented by Dr. James Spencer, the grant recipient and study investigator, in a poster session at the 2010 Orlando Dermatology Conference taking place in Orlando, Florida January 15-18th.

19 Jan 2010

NIH awards 12 research grants totaling $5 million for Tβ4 research

REGENERX BIOPHARMACEUTICALS, INC. announced today that National Institutes of Health (NIH) has awarded 12 research grants totaling over $5,000,000 for the study of Tβ4 in 2009/2010. Many of these grants will be going to collaborators with whom RegeneRx is working to understand its numerous biological activities and capabilities in medical indications, including the role of Tβ4 as an anti-inflammatory agent in tissue regeneration and its promotion of stem cell maturation.

13 Jan 2010

NitricBio chooses Clinipace Worldwide to manage and conduct two phase 3 trials

Clinipace Worldwide, a global technology-driven clinical research organization (CRO), announced today that NitricBio has selected the company to manage and deploy multiple studies in support of medical applications of topical nitric oxide gas (gNO).

13 Jan 2010

Grossman Burn Foundation receives Fraxel re:store laser system from Solta Medical

Solta Medical, Inc. today announced the donation of a Fraxel re:store laser system to the Grossman Burn Foundation, the philanthropic arm of the Grossman Burn Center, a worldwide leader in innovative treatment and care for burn patients and their families.

12 Jan 2010

AUA updates clinical practice guideline on female stress urinary incontinence

A complete evaluation, including an assessment of post-void residual volume, is key when evaluating a female patient for surgery to treat stress urinary incontinence (SUI), according to a new clinical practice guideline released today by the American Urological Association (AUA).

8 Jan 2010

ART publishes impressive data on its bioresorbable stent

Arterial Remodeling Technologies (“ART”) announced today that it has disclosed impressive in vivo and in vitro data related to its bioresorbable stent platform—data that validates the Company’s approach to simultaneously balance biocompatibility, biomechanics and bioresorption in a bioresorbable PLA (polylactic acid) stent without altering healing by drug elution from the stent platform.

5 Jan 2010

Smith & Nephew adds PELNAC dermal replacement wound product to its portfolio

Smith & Nephew (LSE: SN) Advanced Wound Management division, announces the agreement to partner with Gunze Limited, Japan and exclusively distribute PELNAC dermal replacement in Japan, South Africa, Australia and New Zealand.

24 Dec 2009

MiMedx Group launches its Paradis Vaso Shield vessel cover product

MiMedx Group, Inc. announced today that it has officially launched its first product, Paradis Vaso Shield(TM). In April 2009, The Food and Drug Administration cleared the Vaso Shield for use as a cover for vessels following anterior vertebral surgeries. The Vaso Shield is a permanent and transparent hydrogel product protected by multiple patents and patent applications, as well as a proprietary manufacturing process.

24 Dec 2009

Findings may lead to new methods for diagnosing osteoporosis

Using a technique that provides detailed images of nanoscale structures, researchers at the University of Michigan and Detroit's Henry Ford Hospital have discovered changes in the collagen component of bone that directly relate to bone health.

23 Dec 2009

Researchers develop new approach for treating and healing skin abscesses

Researchers at the Albert Einstein College of Medicine of Yeshiva University have developed a new approach for treating and healing skin abscesses caused by bacteria resistant to most antibiotics.

23 Dec 2009

Suneva Medical and WTI sign credit agreement to expand growth objectives

Suneva Medical, a privately-held aesthetic medical device company, today announced that it has signed a multi-million dollar line of credit facility with Western Technology Investment (WTI).

17 Dec 2009

Osteotech submits Duratech BioRegeneration Matrix 510(k) application to the FDA

Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that it has submitted a 510(k) application to the United States Food and Drug Administration (FDA) to obtain marketing clearance for the use of its Duratech(TM) BioRegeneration Matrix to repair or replace the dura mater (the outermost membrane surrounding the brain) in various cranial surgical procedures.

17 Dec 2009

HFU increases mortality among diabetics, says report

Cardium Therapeutics today reported on recent clinical findings published in the December issue of Diabetes Care showing an increase in mortality in diabetic patients with a history of foot ulcer (HFU) compared with diabetic patients without HFU and with non-diabetic patients.

17 Dec 2009

Top-line efficacy and safety results from Phase 2b clinical trial of XIAFLEX announced

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced top-line efficacy and safety results from a Phase 2b clinical trial of XIAFLEX(TM) for the treatment of Peyronie's disease.

17 Dec 2009

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced top-line efficacy and safety results for the phase IIb clinical trial for XIAFLEX™ (collagenase clostridium histolyticum) in the treatment of Peyronie's disease.

16 Dec 2009